Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akorn Inc (AKRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 557,176
  • Shares Outstanding, K 125,492
  • Annual Sales, $ 841,050 K
  • Annual Income, $ -24,550 K
  • 36-Month Beta 2.79
  • Price/Sales 0.77
  • Price/Cash Flow 8.23
  • Price/Book 0.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.04
  • Low Estimate -0.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.49 +27.22%
on 01/22/19
4.47 -0.67%
on 02/15/19
+0.57 (+14.73%)
since 01/15/19
3-Month
3.14 +41.40%
on 01/02/19
7.25 -38.76%
on 11/23/18
-2.51 (-36.12%)
since 11/15/18
52-Week
3.14 +41.40%
on 01/02/19
31.98 -86.12%
on 02/16/18
-27.51 (-86.10%)
since 02/15/18

Most Recent Stories

More News
EQUITY ALERT: Rosen Law Firm Continues to Investigate Securities Claims Against Akorn, Inc. - AKRX

Rosen Law Firm, a global investor rights law firm, announces it is continuing to investigate potential securities claims on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) resulting from allegations...

AKRX : 4.44 (+2.54%)
Specialty Generics 2019 Global Opportunity Analysis And Industry Forecasts To 2022

VRX.TO : 30.80 (-3.33%)
NVS : 89.88 (+0.97%)
AKRX : 4.44 (+2.54%)
PFE : 42.40 (+1.02%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akorn, Inc. ("Akorn" or "the Company") (NASDAQ: AKRX) for violations...

AKRX : 4.44 (+2.54%)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Akorn, Inc. - AKRX

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Akorn, Inc. (NASDAQ: AKRX) resulting from allegations...

AKRX : 4.44 (+2.54%)
Akorn, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX) and certain of its...

AKRX : 4.44 (+2.54%)
Watch for Akorn Inc to Potentially Pullback After Gaining 2.72% Yesterday

Akorn Inc (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $3.77 to a high of $3.80. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $3.76...

AKRX : 4.44 (+2.54%)
Ocular Inflammation Treatment Market is set to Grow US$ 500 Billion by 2024

New York, January 16, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

VRX.TO : 30.80 (-3.33%)
ALIM : 1.08 (unch)
AGN : 139.07 (+0.29%)
NVS : 89.88 (+0.97%)
AKRX : 4.44 (+2.54%)
PFE : 42.40 (+1.02%)
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

MYL : 31.84 (+1.02%)
RDY : 35.98 (-4.59%)
MNK : 21.81 (+0.14%)
AKRX : 4.44 (+2.54%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akorn, Inc. - AKRX

Pomerantz LLP is investigating claims on behalf of investors of Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AKRX : 4.44 (+2.54%)
Micron and Intuitive Surgical jump while Constellation skids

NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:

LEN : 48.90 (+1.37%)
STZ : 174.91 (+0.55%)
MU : 41.99 (-0.57%)
NBL : 22.64 (+2.86%)
DLR : 115.03 (+1.07%)
ISRG : 548.50 (+2.32%)
AKRX : 4.44 (+2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AKRX with:

Business Summary

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals,...

See More

Key Turning Points

2nd Resistance Point 4.59
1st Resistance Point 4.52
Last Price 4.44
1st Support Level 4.32
2nd Support Level 4.19

See More

52-Week High 31.98
Fibonacci 61.8% 20.96
Fibonacci 50% 17.56
Fibonacci 38.2% 14.16
Last Price 4.44
52-Week Low 3.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar